Skip to content

Our Proprietary Cellular Immunotherapy Platforms

With intelligent engineering, we are developing next-generation induced Pluripotent Stem Cell (iPSC)-derived natural killer (iNK) cells and macrophages (iMACs) to lead the fight against cancer.

Our platforms are built on a deep understanding of iPSC differentiation, immune cell biology and genetic engineering that enable the development of iNK cells and iMACs as allogeneic “off-the-shelf” cellular immunotherapies designed for durability, scalability, safety and efficacy. Our iPSC approach enables multiplex editing and results in products that are clonal in nature and therefore homogenous and well characterized, properties that we believe will enable an efficient approach to manufacturing.

iPSC Approach

Our iPSC-based approach creates a modular system whereby each program can serve as a foundation for further gene editing, which we believe enables the development of a robust pipeline. These edits have the potential to convey additional unique benefits to further optimize the therapeutic profile of our cellular immunotherapies.


Natural killer cells have an innate ability to selectively target cancer cells while leaving healthy cells unharmed. NK cells act through multiple mechanisms, such as cell lysis, secretion of proinflammatory cytokines and antibody-dependent cellular cytotoxicity (ADCC).

Shoreline’s iNK cells are genetically engineered for improved performance through the deletion of the gene encoding cytokine-inducible SH2 containing protein (CISH), a critical negative regulator of NK cell function. Our CISH knock out iNK cells are designed to enhance durability and activity for optimal performance in hematologic and solid tumor settings.


Macrophage cellular immunotherapies are a largely untapped modality with significant therapeutic potential in a wide variety of disease indications from oncology to inflammatory disease and fibrosis. We are developing engineered anti-tumor macrophages, to change the tumor microenvironment and reset the anti-tumor immune response. Leveraging our expertise in iPSC modification and differentiation we are engineering iPSCs that can be differentiated into pro-inflammatory iMACs capable of killing tumor cells via phagocytosis and further stimulate an anti-tumor immune response through the secretion of pro-inflammatory cytokines and the presentation of tumor associated antigens.